We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

55 hedge funds and large institutions have $107M invested in Applied Therapeutics in 2023 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

221,267% more call options, than puts

Call options by funds: $19.9M | Put options by funds: $9K

214% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 7

166% more capital invested

Capital invested by funds: $40.3M → $107M (+$66.7M)

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

100% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 7

38% more funds holding

Funds holding: 4055 (+15)

13.69% more ownership

Funds ownership: 54.39%68.08% (+14%)

Holders
55
Holders Change
+15
Holders Change %
+37.5%
% of All Funds
0.87%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
22
Increased
14
Reduced
7
Closed
7
Calls
$19.9M
Puts
$9K
Net Calls
+$19.9M
Net Calls Change
+$10.3M

APLT Hedge Fund Activity: Q3 2023 in Review

55 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q3 2023, worth a combined $107M — up 166% from $40.3M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new APLT positions and 7 closed out — a net gain of 15 holders — while 14 added to existing stakes and 7 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $5.6M. The largest seller was CM Management, exiting entirely with an estimated $384K sold.

  • 55 institutional investors held Applied Therapeutics (APLT) as of Q3 2023, up from 40 in Q2 2023.
  • Funds reported $107M of Applied Therapeutics stock for Q3 2023, up 166% quarter-over-quarter.
  • 22 funds opened new Applied Therapeutics positions in Q3 2023 and 7 closed out, a net change of +15 holders.
  • The largest Applied Therapeutics buyer in Q3 2023 was Armistice Capital, an estimated $5.6M added.
  • The largest Applied Therapeutics seller in Q3 2023 was CM Management, an estimated $384K sold.

Based on aggregated 13F filings for Q3 2023.